Status: Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Participants needed: 165
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Pheon TherapeuticsUpdated: Jun 5, 2026Locations: 20
Eligibility criteria
Colorectal adenocarcinoma (CRC), or [+7]
Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload. [+6]